Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, marketed as Zepbound for weight management, demonstrates substantial weight reduction in published clinical trials. The medication works by activating both GLP-1 and GIP receptors, signaling the brain to reduce hunger and increase fullness. Understanding realistic weight loss expectations helps patients set achievable goals and stay motivated throughout treatment.

Clinical Trial Weight Loss Data for Tirzepatide

The pivotal SUMO trials evaluated tirzepatide's effectiveness across three phases. In SUMO 3, patients receiving the highest maintenance dose lost an average of 22.5% of their starting weight over 68 weeks, compared to 2.3% in the placebo group. SUMO 4 tracked similar outcomes in patients with type 2 diabetes, showing weight reductions ranging from 12% to 21% depending on the maintenance dose level.

These results represent some of the largest weight loss percentages achieved by any approved medication in this class. Critically, weight loss continued throughout the trial period, suggesting sustained efficacy without a plateau. Most patients reached their maximum dose by week 16, allowing sufficient time to evaluate their individual response before continuing long-term.

Why Weight Loss Varies From Person to Person

Genetic differences in peptide receptor sensitivity explain why two patients on identical tirzepatide doses may experience different weight loss trajectories. Key genetic variants in the GLP1R and GIPR genes influence how strongly your cells respond to the medication's signals. Metabolic rate, baseline weight, age, and physical activity level also significantly impact the speed and magnitude of weight reduction.

PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and 150+ genetic insights, including variants like GLP1R rs6923761 and GIPR rs1800437, to identify your individual peptide-pathway predispositions. This personalized approach allows your healthcare provider to anticipate your likely response category and adjust your treatment plan accordingly. Understanding your genetic profile removes guesswork from dosing decisions.

Realistic Weight Loss Timeline on Tirzepatide

Most patients notice the first signs of appetite reduction within 1–2 weeks of starting tirzepatide. Measurable weight loss typically appears by week 4, though initial drops often reflect water loss and reduced food volume. Steady, consistent weight loss of 1–2 pounds per week becomes the pattern for most users by weeks 8–12 as the medication reaches therapeutic levels.

The most dramatic weight loss phases occur between weeks 8 and 20, when patients have reached stable doses and their bodies have fully adapted to the medication's hunger-suppressing effects. After week 24, the rate of weight loss may slow as patients approach a new metabolic equilibrium, though continued gradual reduction often continues through week 68 and beyond. Stopping the medication typically results in gradual weight regain over several months, making ongoing use essential for maintaining results.

Maximizing Your Tirzepatide Results at PlexusDx

PlexusDx offers Compounded Tirzepatide Injection starting at $249/month, with no membership fees, insurance requirements, or flat per-compound pricing adjustments. Your dose may need to go up. Your price won't. All medications come from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality and sterility. PlexusDx serves all 50 states and accepts HSA/FSA accounts for added affordability.

Pairing medication with consistent eating habits, regular movement, and adequate sleep produces the strongest outcomes. The Precision Peptide Genetic Test ($99 add-on after your first month) provides personalized guidance on which metabolic pathways respond best in your body, helping you and your provider fine-tune your approach. Regular follow-up visits allow your provider to monitor progress, adjust your dose safely, and address any side effects before they become problematic.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose on Zepbound in the first month?

Initial weight loss in the first month averages 2–5 pounds for most patients, primarily from reduced appetite and decreased food intake. Significant loss typically accelerates by week 4–8 as the medication reaches full effectiveness. Your individual result depends on your starting weight, adherence, and how your body's GLP-1 and GIP receptors respond to tirzepatide.

Is 22% weight loss realistic for someone starting tirzepatide?

Yes. Clinical trials show that patients on the highest maintenance dose lost an average of 22.5% of body weight over 68 weeks. However, typical patients on moderate doses lose 15–18%, and some lose less depending on genetics, lifestyle, and adherence. PlexusDx's Precision Peptide Genetic Test helps predict your likely response range based on your unique peptide-pathway genetics.

How does PlexusDx's tirzepatide pricing work?

PlexusDx Compounded Tirzepatide Injection starts at $249/month flat, with no your dose may need to go up - your price won't increases. No insurance, membership fees, or hidden charges apply. The medication is prepared by licensed 503A compounding pharmacies, and PlexusDx serves all 50 states. HSA/FSA funds are accepted.

Do people regain weight after stopping tirzepatide?

Yes. Most patients gradually regain weight after stopping the medication, as appetite and hunger signals return to baseline. Studies show weight typically stabilizes 50–80% higher than the lowest point reached on medication. Continuing treatment is necessary to maintain weight loss benefits long-term.

How can genetic testing help predict my weight loss on tirzepatide?

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to tirzepatide's dual mechanism. Testing identifies your metabolic predispositions across 14 pathways and 150+ genetic insights, allowing your provider to predict your likely response category and personalize your treatment from day one.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves